MET and non-small cell lung carcinoma: This is supported by a recent analysis by Koeppen et al [65], in which MET copy number (cut-off ≥ 5 copies/cell by FISH) was inferior to MET IHC staining as a predictive marker of benefit from onartuzumab in patients with NSCLC.